All
Niraparib Improves Outcomes for Patients With Ovarian Cancer
June 29th 2016Maintenance treatment with the novel agent niraparib improved progression-free survival (PFS) compared with placebo for patients with recurrent ovarian cancer harboring a germline BRCA (gBRCA) mutation or homologous recombination deficiency (HRD).